eisai - Search News

Eisai, Merck and Keytruda

Reuters on MSN · 2d

Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a type of esophageal cancer in a late-stage trial. The trial was studying U.S. drugmaker Merck's blockbuster immunotherapy Keytruda and Eisai's Lenvima,

FiercePharma · 2d

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. | Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way.

Benzinga.com · 2d

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve overall survival in patients with a type of esophageal cancer in a late-stage trial,

Investing.com on MSN · 2d

Merck and Eisai report mixed results in Phase 3 cancer trial

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, which evaluated the efficacy of the combination therapy KEYTRUDA and LENVIMA for patients with advanced gastroesophageal adenocarcinoma.

Eisai, Biogen and Alzheimer's disease

Hosted on MSN · 10h

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug received standard U.

Business Insider · 9h

FDA approves Eisai, Biogen’s sBLA for lecanemab-irmb IV dosing

Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has approved the Supplemental Biologics License

USFDA nod to Leqembi IV maintenance dosing for treatment of early Alzheimer's Disease: Eisai, Biogen

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four

GlobalData on MSN2d

MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed success

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

BioPharma Dive2d

Mixed results for Keytruda; AbbVie to work with Neomorph

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results